<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31663">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02694484</url>
  </required_header>
  <id_info>
    <org_study_id>I15033 TRANSFECMV</org_study_id>
    <nct_id>NCT02694484</nct_id>
  </id_info>
  <brief_title>Search Cytomegalovirus in Healthy Volunteers Stools Samples Selected as Potential Donor for Fecal Microbiota Transplant</brief_title>
  <acronym>TRANSFECMV</acronym>
  <official_title>Search Cytomegalovirus (CMV) in Healthy Volunteers Stools Samples Selected as Potential Donor for Fecal Microbiota Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fecal microbiota transplantation (FMT) is recommended in the treatment of recurrent
      Clostridium difficile infection (CDI). The principle is to administer a fecal suspension of
      a healthy subject (donor) in the digestive tract of a patient with an CDI (receiver). Donors
      are being clinical and laboratory screening to reduce the likelihood of pathogens
      transmission (infectious and other). Cytomegalovirus (CMV) is part of the examinations
      requested by the Agence national de sécurité du médicament et des produits de santé in the
      context of clinical research. A sero-matching between donor and recipient CMV is requested.
      This recommendation eliminates many potential donors to a recipient. To date, the frequency
      detection level of CMV in stool in healthy volunteers with documented positive CMV serology
      is not known. In addition, CMV transmission risk via the stool is not established. This
      study aims to determine the detection frequency of CMV in healthy volunteers stool samples
      selected as potential donors for a FMT and having a positive CMV serology documented
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection frequency of CMV</measure>
    <time_frame>30 days</time_frame>
    <description>Detection frequency of CMV in healthy volunteers stool samples with the selection criteria for the gift of fecal microbiota and having a CMV positive serology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of CMV in the stool and in blood.</measure>
    <time_frame>At day 30</time_frame>
    <description>Evaluation of the link between the presence of CMV in the stool and the detection of CMV viral load in whole blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infectivity of CMV present in faecal</measure>
    <time_frame>At day 30</time_frame>
    <description>Evaluation of the infectivity of CMV present in faecal</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>CMV</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>For healthy volunteers corresponding to the inclusion criteria it will be taken them Blood and stool samples : a blood sample during the inclusion visit and if they are seropositive for the CMV, it will be taken them another blood sample and they will give a stool sample for the following visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood and stool samples</intervention_name>
    <description>Blood sample at Day 1 and blood and stool sample at the next visit</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged over 18 and under 65 years

          -  Having a normal transit (less than three stools per day and more than three bowel
             movements per week)

          -  Body mass index (BMI) &lt;30 and&gt; 16.9

          -  Accept the constraints of the study, ie two visits (inclusion and Following Visit), a
             stool sample, two blood tests

          -  Having given and signed informed consent

          -  Being affiliated or beneficiary of a social security scheme

        Exclusion Criteria:

          -  Taking a treatment with anti-CMV action in three months by acyclovir, valacyclovir,
             ganciclovir, valganciclovir, foscarnet, cidofovir, brincidofovir

          -  Having an absolute exclusion criteria to donation defined by the survey of French
             Group Fecal Transplant:

          -  Digestive disorders (acute or chronic diarrhea) in the three months prior to donation

          -  Known chronic disease (except hypertension and hypercholesterolemia)

          -  Documented history of typhoid fever

          -  Taking long-term medication (except contraceptives, cholesterol-lowering and
             antihypertensive treatment)

          -  Antibiotic taken within three months

          -  Stay in tropics during the three months prior to donation,

          -  Residence of several years in tropics (over 24 months)

          -  Hospitalization abroad of more than 24 hours in the last 12 months to the donor or
             his entourage (those living under the same roof)

          -  Healthy Volunteers who have not reached the limit of compensation by social security
             or exclusion period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sophie ALAIN, MD</last_name>
    <phone>0555056728</phone>
    <email>sophie.alain@chu-limoges.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tatiana GALPERINE, MD</last_name>
    <phone>0320445743</phone>
    <email>Tatiana.galperine@chru-lille.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de biologie pathologie / Laboratoire de virologie</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cic 1403-Crb Inserm-Chu</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique DEPLANQUE, MD</last_name>
      <email>dominique.deplanque@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Dominique DEPLANQUE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria-Claire MIGAUD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cic - Inserm - 1435</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah POSTIL, MD</last_name>
      <phone>0555054067</phone>
      <email>deborah.postil@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Deborah POSTIL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas LAFIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Bactériologie-Virologie-Hygiène/CNR des Cytomégalovirus</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 29, 2016</lastchanged_date>
  <firstreceived_date>December 7, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cytomegalovirus</keyword>
  <keyword>Stool sample</keyword>
  <keyword>Healthy Volunteers</keyword>
  <keyword>Fecal microbiota transplant</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
